Eintrag weiter verarbeiten
Multiomics Analysis Reveals that GLS and GLS2 Differentially Modulate the Clinical Outcomes of Cancer
Gespeichert in:
| Zeitschriftentitel: | Journal of Clinical Medicine |
|---|---|
| Personen und Körperschaften: | , , , , , |
| In: | Journal of Clinical Medicine, 8, 2019, 3, S. 355 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
MDPI AG
|
| Schlagwörter: |
| author_facet |
Saha, Subbroto Islam, S.M. Abdullah-AL-Wadud, M. Islam, Saiful Ali, Farman Park, Kyoung Saha, Subbroto Islam, S.M. Abdullah-AL-Wadud, M. Islam, Saiful Ali, Farman Park, Kyoung |
|---|---|
| author |
Saha, Subbroto Islam, S.M. Abdullah-AL-Wadud, M. Islam, Saiful Ali, Farman Park, Kyoung |
| spellingShingle |
Saha, Subbroto Islam, S.M. Abdullah-AL-Wadud, M. Islam, Saiful Ali, Farman Park, Kyoung Journal of Clinical Medicine Multiomics Analysis Reveals that GLS and GLS2 Differentially Modulate the Clinical Outcomes of Cancer General Medicine |
| author_sort |
saha, subbroto |
| spelling |
Saha, Subbroto Islam, S.M. Abdullah-AL-Wadud, M. Islam, Saiful Ali, Farman Park, Kyoung 2077-0383 MDPI AG General Medicine http://dx.doi.org/10.3390/jcm8030355 <jats:p>Kidney-type glutaminase (GLS) and liver-type glutaminase (GLS2) are dysregulated in many cancers, making them appealing targets for cancer therapy. However, their use as prognostic biomarkers is controversial and remains an active area of cancer research. Here, we performed a systematic multiomic analysis to determine whether glutaminases function as prognostic biomarkers in human cancers. Glutaminase expression and methylation status were assessed and their prominent functional protein partners and correlated genes were identified using various web-based bioinformatics tools. The cross-cancer relationship of glutaminases with mutations and copy number alterations was also investigated. Gene ontology (GO) and pathway analysis were performed to assess the integrated effect of glutaminases and their correlated genes on various cancers. Subsequently, the prognostic roles of GLS and GLS2 in human cancers were mined using univariate and multivariate survival analyses. GLS was frequently over-expressed in breast, esophagus, head-and-neck, and blood cancers, and was associated with a poor prognosis, whereas GLS2 overexpression implied poor overall survival in colon, blood, ovarian, and thymoma cancers. Both GLS and GLS2 play oncogenic and anti-oncogenic roles depending on the type of cancer. The varying prognostic characteristics of glutaminases suggest that GLS and GLS2 expression differentially modulate the clinical outcomes of cancers.</jats:p> Multiomics Analysis Reveals that GLS and GLS2 Differentially Modulate the Clinical Outcomes of Cancer Journal of Clinical Medicine |
| doi_str_mv |
10.3390/jcm8030355 |
| facet_avail |
Online Free |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMzM5MC9qY204MDMwMzU1 |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMzM5MC9qY204MDMwMzU1 |
| institution |
DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Rs1 DE-Pl11 |
| imprint |
MDPI AG, 2019 |
| imprint_str_mv |
MDPI AG, 2019 |
| issn |
2077-0383 |
| issn_str_mv |
2077-0383 |
| language |
English |
| mega_collection |
MDPI AG (CrossRef) |
| match_str |
saha2019multiomicsanalysisrevealsthatglsandgls2differentiallymodulatetheclinicaloutcomesofcancer |
| publishDateSort |
2019 |
| publisher |
MDPI AG |
| recordtype |
ai |
| record_format |
ai |
| series |
Journal of Clinical Medicine |
| source_id |
49 |
| title |
Multiomics Analysis Reveals that GLS and GLS2 Differentially Modulate the Clinical Outcomes of Cancer |
| title_unstemmed |
Multiomics Analysis Reveals that GLS and GLS2 Differentially Modulate the Clinical Outcomes of Cancer |
| title_full |
Multiomics Analysis Reveals that GLS and GLS2 Differentially Modulate the Clinical Outcomes of Cancer |
| title_fullStr |
Multiomics Analysis Reveals that GLS and GLS2 Differentially Modulate the Clinical Outcomes of Cancer |
| title_full_unstemmed |
Multiomics Analysis Reveals that GLS and GLS2 Differentially Modulate the Clinical Outcomes of Cancer |
| title_short |
Multiomics Analysis Reveals that GLS and GLS2 Differentially Modulate the Clinical Outcomes of Cancer |
| title_sort |
multiomics analysis reveals that gls and gls2 differentially modulate the clinical outcomes of cancer |
| topic |
General Medicine |
| url |
http://dx.doi.org/10.3390/jcm8030355 |
| publishDate |
2019 |
| physical |
355 |
| description |
<jats:p>Kidney-type glutaminase (GLS) and liver-type glutaminase (GLS2) are dysregulated in many cancers, making them appealing targets for cancer therapy. However, their use as prognostic biomarkers is controversial and remains an active area of cancer research. Here, we performed a systematic multiomic analysis to determine whether glutaminases function as prognostic biomarkers in human cancers. Glutaminase expression and methylation status were assessed and their prominent functional protein partners and correlated genes were identified using various web-based bioinformatics tools. The cross-cancer relationship of glutaminases with mutations and copy number alterations was also investigated. Gene ontology (GO) and pathway analysis were performed to assess the integrated effect of glutaminases and their correlated genes on various cancers. Subsequently, the prognostic roles of GLS and GLS2 in human cancers were mined using univariate and multivariate survival analyses. GLS was frequently over-expressed in breast, esophagus, head-and-neck, and blood cancers, and was associated with a poor prognosis, whereas GLS2 overexpression implied poor overall survival in colon, blood, ovarian, and thymoma cancers. Both GLS and GLS2 play oncogenic and anti-oncogenic roles depending on the type of cancer. The varying prognostic characteristics of glutaminases suggest that GLS and GLS2 expression differentially modulate the clinical outcomes of cancers.</jats:p> |
| container_issue |
3 |
| container_start_page |
0 |
| container_title |
Journal of Clinical Medicine |
| container_volume |
8 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792343242386178062 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T16:48:34.589Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Multiomics+Analysis+Reveals+that+GLS+and+GLS2+Differentially+Modulate+the+Clinical+Outcomes+of+Cancer&rft.date=2019-03-13&genre=article&issn=2077-0383&volume=8&issue=3&pages=355&jtitle=Journal+of+Clinical+Medicine&atitle=Multiomics+Analysis+Reveals+that+GLS+and+GLS2+Differentially+Modulate+the+Clinical+Outcomes+of+Cancer&aulast=Park&aufirst=Kyoung&rft_id=info%3Adoi%2F10.3390%2Fjcm8030355&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792343242386178062 |
| author | Saha, Subbroto, Islam, S.M., Abdullah-AL-Wadud, M., Islam, Saiful, Ali, Farman, Park, Kyoung |
| author_facet | Saha, Subbroto, Islam, S.M., Abdullah-AL-Wadud, M., Islam, Saiful, Ali, Farman, Park, Kyoung, Saha, Subbroto, Islam, S.M., Abdullah-AL-Wadud, M., Islam, Saiful, Ali, Farman, Park, Kyoung |
| author_sort | saha, subbroto |
| container_issue | 3 |
| container_start_page | 0 |
| container_title | Journal of Clinical Medicine |
| container_volume | 8 |
| description | <jats:p>Kidney-type glutaminase (GLS) and liver-type glutaminase (GLS2) are dysregulated in many cancers, making them appealing targets for cancer therapy. However, their use as prognostic biomarkers is controversial and remains an active area of cancer research. Here, we performed a systematic multiomic analysis to determine whether glutaminases function as prognostic biomarkers in human cancers. Glutaminase expression and methylation status were assessed and their prominent functional protein partners and correlated genes were identified using various web-based bioinformatics tools. The cross-cancer relationship of glutaminases with mutations and copy number alterations was also investigated. Gene ontology (GO) and pathway analysis were performed to assess the integrated effect of glutaminases and their correlated genes on various cancers. Subsequently, the prognostic roles of GLS and GLS2 in human cancers were mined using univariate and multivariate survival analyses. GLS was frequently over-expressed in breast, esophagus, head-and-neck, and blood cancers, and was associated with a poor prognosis, whereas GLS2 overexpression implied poor overall survival in colon, blood, ovarian, and thymoma cancers. Both GLS and GLS2 play oncogenic and anti-oncogenic roles depending on the type of cancer. The varying prognostic characteristics of glutaminases suggest that GLS and GLS2 expression differentially modulate the clinical outcomes of cancers.</jats:p> |
| doi_str_mv | 10.3390/jcm8030355 |
| facet_avail | Online, Free |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMzM5MC9qY204MDMwMzU1 |
| imprint | MDPI AG, 2019 |
| imprint_str_mv | MDPI AG, 2019 |
| institution | DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Rs1, DE-Pl11 |
| issn | 2077-0383 |
| issn_str_mv | 2077-0383 |
| language | English |
| last_indexed | 2024-03-01T16:48:34.589Z |
| match_str | saha2019multiomicsanalysisrevealsthatglsandgls2differentiallymodulatetheclinicaloutcomesofcancer |
| mega_collection | MDPI AG (CrossRef) |
| physical | 355 |
| publishDate | 2019 |
| publishDateSort | 2019 |
| publisher | MDPI AG |
| record_format | ai |
| recordtype | ai |
| series | Journal of Clinical Medicine |
| source_id | 49 |
| spelling | Saha, Subbroto Islam, S.M. Abdullah-AL-Wadud, M. Islam, Saiful Ali, Farman Park, Kyoung 2077-0383 MDPI AG General Medicine http://dx.doi.org/10.3390/jcm8030355 <jats:p>Kidney-type glutaminase (GLS) and liver-type glutaminase (GLS2) are dysregulated in many cancers, making them appealing targets for cancer therapy. However, their use as prognostic biomarkers is controversial and remains an active area of cancer research. Here, we performed a systematic multiomic analysis to determine whether glutaminases function as prognostic biomarkers in human cancers. Glutaminase expression and methylation status were assessed and their prominent functional protein partners and correlated genes were identified using various web-based bioinformatics tools. The cross-cancer relationship of glutaminases with mutations and copy number alterations was also investigated. Gene ontology (GO) and pathway analysis were performed to assess the integrated effect of glutaminases and their correlated genes on various cancers. Subsequently, the prognostic roles of GLS and GLS2 in human cancers were mined using univariate and multivariate survival analyses. GLS was frequently over-expressed in breast, esophagus, head-and-neck, and blood cancers, and was associated with a poor prognosis, whereas GLS2 overexpression implied poor overall survival in colon, blood, ovarian, and thymoma cancers. Both GLS and GLS2 play oncogenic and anti-oncogenic roles depending on the type of cancer. The varying prognostic characteristics of glutaminases suggest that GLS and GLS2 expression differentially modulate the clinical outcomes of cancers.</jats:p> Multiomics Analysis Reveals that GLS and GLS2 Differentially Modulate the Clinical Outcomes of Cancer Journal of Clinical Medicine |
| spellingShingle | Saha, Subbroto, Islam, S.M., Abdullah-AL-Wadud, M., Islam, Saiful, Ali, Farman, Park, Kyoung, Journal of Clinical Medicine, Multiomics Analysis Reveals that GLS and GLS2 Differentially Modulate the Clinical Outcomes of Cancer, General Medicine |
| title | Multiomics Analysis Reveals that GLS and GLS2 Differentially Modulate the Clinical Outcomes of Cancer |
| title_full | Multiomics Analysis Reveals that GLS and GLS2 Differentially Modulate the Clinical Outcomes of Cancer |
| title_fullStr | Multiomics Analysis Reveals that GLS and GLS2 Differentially Modulate the Clinical Outcomes of Cancer |
| title_full_unstemmed | Multiomics Analysis Reveals that GLS and GLS2 Differentially Modulate the Clinical Outcomes of Cancer |
| title_short | Multiomics Analysis Reveals that GLS and GLS2 Differentially Modulate the Clinical Outcomes of Cancer |
| title_sort | multiomics analysis reveals that gls and gls2 differentially modulate the clinical outcomes of cancer |
| title_unstemmed | Multiomics Analysis Reveals that GLS and GLS2 Differentially Modulate the Clinical Outcomes of Cancer |
| topic | General Medicine |
| url | http://dx.doi.org/10.3390/jcm8030355 |